Watching a garage experiment turn into a medical revolution is nothing short of remarkable. Remedy Robotics just closed a $35M Series B led by DCVC, with Blackbird Ventures, KdT Ventures, and Build Collective all jumping in. That’s not small money, it’s conviction. The kind of conviction that says, “Yeah, this is the future of stroke care, and we’re betting on it.”
David Bell built this company in 2020 with a simple but heavy idea: what if geography stopped deciding who lived and who didn’t during a stroke? It’s the type of question that keeps doctors up at night and engineers caffeinated past dawn. Bell, a former physician and Stanford MBA, took that frustration and turned it into robotics that operate on arteries with sub-millimeter precision, from hundreds or even thousands of miles away. The result: the N1 System, the world’s first fully remote endovascular robot.
The concept feels almost cinematic. A stroke patient in Toronto, an interventionalist in San Francisco, connected not by geography but by bandwidth. In Dec 2024, Unity Health Toronto became the stage for the world’s first fully robotic endovascular procedures. Less than a year later, the same N1 System enabled fully remote neuro interventions. That’s not evolution, it’s teleportation for medicine.
Behind the tech sits a platform built like it was designed for NASA: ROS-based control framework, Python-driven machine learning algorithms, AWS cloud backbone, and an edge compute fail-safe that never blinks. The system learns from each navigation, predicts complications before they happen, and integrates seamlessly with existing hospital imaging. It’s precise, compliant (HIPAA, ISO13485), and already protected by 11 filed patents, including one granted this year for intraluminal device guidance.
Remedy Robotics now employs ~100 people out of its San Francisco HQ, all moving fast toward FDA 510(k) submission in early 2026, CE Mark midyear, and commercial deployment soon after. The $35M will fuel that sprint, scaling manufacturing, building remote operation centers, and expanding AI capabilities to make complex vascular care as accessible as Wi-Fi.
And if you’re wondering about market potential, consider this: 4B people globally don’t have timely access to endovascular treatment. That’s not a statistic, it’s an open frontier. With Bell steering and investors backing the mission, Remedy Robotics isn’t just building robots. It’s reprogramming the limits of medicine.
